Abstract 5106
Background
Obesity is a well-known risk factor for colorectal cancer (CRC), the relative risk being higher in men than in women, and for colon than for rectal cancer. Whether this risk differs by sidedness of colon cancer and sex, has however not yet been explored.
Methods
Among 28098 participants in the Malmö Diet and Cancer study, 11063 men and 17035 women, 584 incident CRC cases had been registered by Dec 31 2008. Seven anthropometric factors; height, weight, bodyfat%, hip circumference, waist circumference, BMI and waist-hip ratio (WHR) were categorized into quartiles (Q). Hazard ratios (HR) of CRC risk according to tumour location (right colon, left colon, rectum) and sex were calculated using multivariable Cox regression models, adjusted for age, smoking, educational level and alcohol intake.
Results
In men, several anthropometric factors were associated with an increased risk of right-sided colon cancer (HR for Q1[ref]-Q4 for weight 1.0, 1.67, 1.99, 2.88, ptrend= 0.001; waist circumference 1.0, 0.64, 1.59, 2.03, ptrend= 0.002; WHR 1.0, 0.73, 1.93, 1.89, ptrend= 0.004; BMI 1.0, 1.29, 1.50, 2.64, ptrend= 0.001), only WHR with left-sided colon cancer (1.0, 1.26, 1.94, 2.06, ptrend= 0.021), and none with rectal cancer. In women, body size was not associated with risk for neither right-sided nor left-sided colon cancer, only with rectal cancer (bodyfat% 1.0, 1.57, 2.18, 1.94, ptrend= 0.032, hip circumference 1.0, 1.76, 1.45, 2.18, ptrend= 0.033). Significant interactions with sex were denoted for hip circumference (p = 0.032) and BMI (p = 0.026) in relation to risk of right-sided colon cancer.
Conclusions
These data unveil a sexual dimorphism in the relationship between obesity and right-sided colon cancer, only being evident in men. As right-sided tumours are otherwise more common in women, hormonal factors may be particularly influential in their carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
The Swedish Cancer Society, the Swedish Research Council, the Swedish Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund University Faculty of Medicine and University Hospital Research Grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2376 - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease
Presenter: Johannes Ettl
Session: Poster Display session 2
Resources:
Abstract
4874 - Complete Responses in Patients With 2nd-Line or Greater Metastatic Triple-Negative Breast Cancer (TNBC) Following First-in-Human Immunotherapy Combining NK and T Cell Activation with Off-the-Shelf High-Affinity CD16 NK Cell Line (haNK)
Presenter: Chaitali Nangia
Session: Poster Display session 2
Resources:
Abstract
4362 - Reproducibility and concordance of 4 clinically developed programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays in triple-negative breast cancer (TNBC)
Presenter: Aurelia Noske
Session: Poster Display session 2
Resources:
Abstract
4528 - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy
Presenter: Peter Kaufman
Session: Poster Display session 2
Resources:
Abstract
4112 - Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
Presenter: Yang Chen
Session: Poster Display session 2
Resources:
Abstract
5699 - Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
Presenter: Joyce O’Shaughnessy
Session: Poster Display session 2
Resources:
Abstract
1931 - Maintenance Chemotherapy is effective in Patients with Metastatic Triple Negative Breast Cancer After First-line Platinum-based Chemotherapy
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract
4696 - Using the Patient-Reported Outcomes Measurement Information System (PROMIS) to investigate symptom burden enrichment in Stage IV patients at an academic center
Presenter: Madeline Matthys
Session: Poster Display session 2
Resources:
Abstract
4582 - Measures of functional status in adults aged ≥70 years with advanced breast cancer (ABC) receiving palbociclib (PAL) combination therapy in POLARIS
Presenter: Meghan Karuturi
Session: Poster Display session 2
Resources:
Abstract
3565 - Real-World 1-Year Survival Analysis of Patients with Metastatic Breast Cancer with Liver or Lung Metastasis Treated with Eribulin, Gemcitabine or Capecitabine
Presenter: Shayma Kazmi
Session: Poster Display session 2
Resources:
Abstract